Navigation Links
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
Date:6/24/2009

PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822.

Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 .

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group."

Please contact:

Dr Fintan Walton, CEO
PharmaVentures Ltd
+44 (0) 1865 784 187

About PharmaVentures Ltd
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored advisory and transaction services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television show www.pharmatelevision.com. Now in its 16th year PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

For further information about PharmaVentures Ltd please contact:
Lisa Holloway
Marketing
+44 (0) 1865 784 177

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2572184.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
2. Online Career Site Assists Academia in Its Reach
3. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
4. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
5. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
6. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
7. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
8. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
9. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
10. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
11. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):